{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:27:10Z","timestamp":1795030030961,"version":"4.10.2"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM150507"],"award-info":[{"award-number":["R35GM150507"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA291723"],"award-info":[{"award-number":["R21CA291723"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA266487"],"award-info":[{"award-number":["R37CA266487"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Eliciting a robust immune response against tumors is often hampered by the inadequate presence of effective antigen presenting cells and their suboptimal ability to present antigens within the immunosuppressive tumor microenvironment. Here, we report a cascade antigen relay strategy integrating antigen capturing nanoparticles (AC-NPs) and migratory type 1 conventional dendritic cells (cDC1s), named Antigen Capturing nanoparticle Transformed Dendritic Cell therapy (ACT-DC), to facilitate in situ immunization. AC-NPs are engineered to capture antigens directly from the tumor and facilitate their delivery to adoptively transferred migratory cDC1s, enhancing antigen presentation to the lymph nodes and reshaping the tumor microenvironment. Our findings suggest that ACT-DC improves in situ antigen collection, triggers a robust systemic immune response without the need for exogenous antigens, and transforms the tumor environment into a more \u201cimmune-hot\u201d state. In multiple tumor models including colon cancer, melanoma, and glioma, ACT-DC in combination with immune checkpoint inhibitors eliminates primary tumors in 50-100% of treated mice and effectively rejects two separate tumor rechallenges. Collectively, ACT-DC could provide a broadly effective approach for in situ cancer immunization and tumor microenvironment modulation.<\/jats:p>","DOI":"10.1038\/s41467-025-59840-w","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:07:02Z","timestamp":1747415222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization"],"prefix":"10.1038","volume":"16","author":[{"given":"Chih-Jia","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong N.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-1136","authenticated-orcid":false,"given":"Edidiong","family":"Udofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caylee","family":"Silvers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-513X","authenticated-orcid":false,"given":"Jiawei","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8213-5492","authenticated-orcid":false,"given":"Qing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philana","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-8692","authenticated-orcid":false,"given":"Sara M.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6847","authenticated-orcid":false,"given":"Joanna E.","family":"Burdette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1349-3759","authenticated-orcid":false,"given":"Steve Seung-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9856-7571","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-844X","authenticated-orcid":false,"given":"Zongmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"59840_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269\u2013281 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"59840_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"59840_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321\u2013334 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"59840_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402\u20131410 (2016).","journal-title":"Nat. Med."},{"key":"59840_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707\u2013716 (2018).","journal-title":"Nat. Biotechnol."},{"key":"59840_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"59840_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"59840_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39330-7","volume":"14","author":"K Adu-Berchie","year":"2023","unstructured":"Adu-Berchie, K. et al. Adoptive T cell transfer and host antigen-presenting cell recruitment with cryogel scaffolds promotes long-term protection against solid tumors. Nat. Commun. 14, 3546 (2023).","journal-title":"Nat. Commun."},{"key":"59840_CR9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213222120","volume":"120","author":"YT Liu","year":"2023","unstructured":"Liu, Y. T. et al. Cytokine conjugation to enhance T cell therapy. Proc. Natl Acad. Sci. USA 120, e2213222120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59840_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41586-022-04772-4","volume":"606","author":"S Badrinath","year":"2022","unstructured":"Badrinath, S. et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature 606, 992\u2013998 (2022).","journal-title":"Nature"},{"key":"59840_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41551-019-0503-3","volume":"4","author":"NJ Shah","year":"2020","unstructured":"Shah, N. J. et al. A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nat. Biomed. Eng. 4, 40\u201351 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"59840_CR12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693\u20131704 (2024).","journal-title":"Nat. Biotechnol."},{"key":"59840_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"QY Hu","year":"2021","unstructured":"Hu, Q. Y. et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat. Biomed. Eng. 5, 1038\u20131047 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"59840_CR14","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974\u2013U1161 (2015).","journal-title":"J. Clin. Oncol."},{"key":"59840_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"59840_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"59840_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"59840_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"59840_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"59840_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"AH Lei","year":"2024","unstructured":"Lei, A. H. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102\u2013116 (2024).","journal-title":"Nat. Immunol."},{"key":"59840_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10588","volume":"9","author":"ME Janes","year":"2023","unstructured":"Janes, M. E., Gottlieb, A. P., Park, K. S., Zhao, Z. M. & Mitragotri, S. Cancer vaccines in the clinic. Bioeng. Transl. Med. 9, e10588 (2023).","journal-title":"Bioeng. Transl. Med."},{"key":"59840_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"KL Yang","year":"2023","unstructured":"Yang, K. L., Halima, A. & Chan, T. A. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat. Rev. Clin. Oncol. 20, 604\u2013623 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"59840_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"59840_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"59840_CR25","doi-asserted-by":"publisher","first-page":"eabm9409","DOI":"10.1126\/sciimmunol.abm9409","volume":"7","author":"E Kvedaraite","year":"2022","unstructured":"Kvedaraite, E. & Ginhoux, F. Human dendritic cells in cancer. Sci. Immunol. 7, eabm9409 (2022).","journal-title":"Sci. Immunol."},{"key":"59840_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner, A. & Ruffell, B. Dendritic cells and cancer immunity. Trends Immunol. 37, 855\u2013865 (2016).","journal-title":"Trends Immunol."},{"key":"59840_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74\u201395 (2017).","journal-title":"Cell Res."},{"key":"59840_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 5408 (2019).","journal-title":"Nat. Commun."},{"key":"59840_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803\u2013808 (2015).","journal-title":"Science"},{"key":"59840_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265\u2013277 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"59840_CR31","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41565-023-01453-9","volume":"18","author":"YB Zhang","year":"2023","unstructured":"Zhang, Y. B. et al. Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy. Nat. Nanotechnol. 18, 1364\u20131374 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"59840_CR32","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013\u20132021 (2006).","journal-title":"Blood"},{"key":"59840_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nm.2074","volume":"16","author":"EJ Villablanca","year":"2010","unstructured":"Villablanca, E. J. et al. Tumor-mediated liver X receptor-\u03b1 activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16, 98\u2013105 (2010).","journal-title":"Nat. Med."},{"key":"59840_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2096363","volume":"11","author":"RS Laureano","year":"2022","unstructured":"Laureano, R. S. et al. Trial watch: dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology 11, 2096363 (2022).","journal-title":"Oncoimmunology"},{"key":"59840_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos, P. M. & Butterfield, L. H. Dendritic cell-based cancer vaccines. J. Immunol. 200, 443\u2013449 (2018).","journal-title":"J. Immunol."},{"key":"59840_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/annonc\/mdx683","volume":"28","author":"A Marabelle","year":"2017","unstructured":"Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28, 33\u201343 (2017).","journal-title":"Ann. Oncol."},{"key":"59840_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911\u2013926 (2022).","journal-title":"Nat. Cancer"},{"key":"59840_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1244","volume":"7","author":"JJ Chen","year":"2021","unstructured":"Chen, J. J. et al. In situ cancer vaccination using lipidoid nanoparticles. Sci. Adv. 7, eabf1244 (2021).","journal-title":"Sci. Adv."},{"key":"59840_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210452","volume":"36","author":"Y Bo","year":"2023","unstructured":"Bo, Y. & Wang, H. Biomaterial-based in situ cancer vaccines. Adv. Mater. 36, e2210452 (2023).","journal-title":"Adv. Mater."},{"key":"59840_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade6257","volume":"9","author":"FR Cheng","year":"2023","unstructured":"Cheng, F. R. et al. Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect. Sci. Adv. 9, eade6257 (2023).","journal-title":"Sci. Adv."},{"key":"59840_CR41","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nnano.2017.113","volume":"12","author":"YZ Min","year":"2017","unstructured":"Min, Y. Z. et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12, 877\u2013882 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"59840_CR42","doi-asserted-by":"publisher","first-page":"e000474","DOI":"10.1136\/jitc-2019-000474","volume":"8","author":"YF Zhou","year":"2020","unstructured":"Zhou, Y. F. et al. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells. J. Immunother. Cancer 8, e000474 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"59840_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35615-5","volume":"14","author":"X Lei","year":"2023","unstructured":"Lei, X. et al. CD4 helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment. Nat. Commun. 14, 217 (2023).","journal-title":"Nat. Commun."},{"key":"59840_CR44","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. & Sousa, C. R. E. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer 4, 784\u2013792 (2018).","journal-title":"Trends Cancer"},{"key":"59840_CR45","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"59840_CR46","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol. Immunol. 20, 432\u2013447 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"59840_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19973-6","volume":"11","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nat. Commun. 11, 6119 (2020).","journal-title":"Nat. Commun."},{"key":"59840_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41551-021-00834-6","volume":"6","author":"WG Wang","year":"2022","unstructured":"Wang, W. G. et al. Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria. Nat. Biomed. Eng. 6, 44\u201353 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"59840_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.chroma.2004.03.032","volume":"1038","author":"M Fountoulakis","year":"2004","unstructured":"Fountoulakis, M., Tsangaris, G., Oh, J. E., Maris, A. & Lubec, G. Protein profile of the HeLa cell line. J. Chromatogr. A 1038, 247\u2013265 (2004).","journal-title":"J. Chromatogr. A"},{"key":"59840_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40821-w","volume":"14","author":"KM Wright","year":"2023","unstructured":"Wright, K. M. et al. Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen. Nat. Commun. 14, 5063 (2023).","journal-title":"Nat. Commun."},{"key":"59840_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","volume":"60","author":"M Matsumoto","year":"2008","unstructured":"Matsumoto, M. & Seya, T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 60, 805\u2013812 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"59840_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23244-3","volume":"12","author":"J Koerner","year":"2021","unstructured":"Koerner, J. et al. PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat. Commun. 12, 2935 (2021).","journal-title":"Nat. Commun."},{"key":"59840_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13046-019-1084-4","volume":"38","author":"L Aurisicchio","year":"2019","unstructured":"Aurisicchio, L. et al. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth. J. Exp. Clin. Cancer Res. 38, 78 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"59840_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00433-9","volume":"7","author":"E Salvatori","year":"2022","unstructured":"Salvatori, E. et al. Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. Npj Vaccines 7, 15 (2022).","journal-title":"Npj Vaccines"},{"key":"59840_CR55","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","volume":"35","author":"C Hernandez","year":"2016","unstructured":"Hernandez, C., Huebener, P. & Schwabe, R. F. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35, 5931\u20135941 (2016).","journal-title":"Oncogene"},{"key":"59840_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.156","volume":"4","author":"O Krysko","year":"2013","unstructured":"Krysko, O., Aaes, T. L., Bachert, C., Vandenabeele, P. & Krysko, D. V. Many faces of DAMPs in cancer therapy. Cell Death Dis. 4, e631 (2013).","journal-title":"Cell Death Dis."},{"key":"59840_CR57","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1182\/blood-2013-12-545772","volume":"124","author":"CT Mayer","year":"2014","unstructured":"Mayer, C. T. et al. Selective and efficient generation of functional Batf3-dependent CD103 dendritic cells from mouse bone marrow. Blood 124, 3081\u20133091 (2014).","journal-title":"Blood"},{"key":"59840_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17704-5","volume":"11","author":"JK Khalsa","year":"2020","unstructured":"Khalsa, J. K. et al. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nat. Commun. 11, 3912 (2020).","journal-title":"Nat. Commun."},{"key":"59840_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37328-9","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat. Commun. 14, 1610 (2023).","journal-title":"Nat. Commun."},{"key":"59840_CR60","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan, A. C. et al. Management of glioblastoma: state of the art and future directions. CA Cancer J. Clin. 70, 299\u2013312 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"59840_CR61","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"59840_CR62","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"JD Brody","year":"2010","unstructured":"Brody, J. D. et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study. J. Clin. Oncol. 28, 4324\u20134332 (2010).","journal-title":"J. Clin. Oncol."},{"key":"59840_CR63","doi-asserted-by":"publisher","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E. & Kroemer, G. Trial watch: STING agonists in cancer therapy. Oncoimmunology 9, 1777624 (2020).","journal-title":"Oncoimmunology"},{"key":"59840_CR64","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","volume":"41","author":"P Meiser","year":"2023","unstructured":"Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498\u20131515.e1410 (2023).","journal-title":"Cancer Cell"},{"key":"59840_CR65","doi-asserted-by":"publisher","first-page":"e000325","DOI":"10.1136\/jitc-2019-000325","volume":"8","author":"L Minute","year":"2020","unstructured":"Minute, L. et al. Cellular cytotoxicity is a form of immunogenic cell death. J. Immunother. Cancer 8, e000325 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"59840_CR66","doi-asserted-by":"publisher","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"AR Sanchez-Paulete","year":"2017","unstructured":"Sanchez-Paulete, A. R. et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann. Oncol. 28, xii44\u2013xii55 (2017).","journal-title":"Ann. Oncol."},{"key":"59840_CR67","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 4, e10143 (2019).","journal-title":"Bioeng. Transl. Med."},{"key":"59840_CR68","doi-asserted-by":"publisher","first-page":"e003827","DOI":"10.1136\/jitc-2021-003827","volume":"10","author":"K Makino","year":"2022","unstructured":"Makino, K. et al. Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling. J. Immunother. Cancer 10, e003827 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"59840_CR69","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3389\/fimmu.2017.01935","volume":"8","author":"P Sachamitr","year":"2018","unstructured":"Sachamitr, P., Leishman, A. J., Davies, T. J. & Fairchild, P. J. Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141 subset. Front Immunol. 8, 1935 (2018).","journal-title":"Front Immunol."},{"key":"59840_CR70","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558\u2013576 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"59840_CR71","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1158\/1078-0432.CCR-19-3642","volume":"26","author":"WX Hong","year":"2020","unstructured":"Hong, W. X. et al. Intratumoral immunotherapy for early-stage solid tumors. Clin. Cancer Res. 26, 3091\u20133099 (2020).","journal-title":"Clin. Cancer Res."},{"key":"59840_CR72","doi-asserted-by":"publisher","first-page":"114505","DOI":"10.1016\/j.addr.2022.114505","volume":"189","author":"A Som","year":"2022","unstructured":"Som, A., Rosenboom, J. G., Chandler, A., Sheth, R. A. & Wehrenberg-Klee, E. Image-guided intratumoral immunotherapy: developing a clinically practical technology. Adv. Drug Deliv. Rev. 189, 114505 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"59840_CR73","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41551-020-00644-2","volume":"5","author":"ZM Zhao","year":"2021","unstructured":"Zhao, Z. M. et al. Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. Nat. Biomed. Eng. 5, 441\u2013454 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"59840_CR74","doi-asserted-by":"publisher","first-page":"eaax9250","DOI":"10.1126\/sciadv.aax9250","volume":"5","author":"ZM Zhao","year":"2019","unstructured":"Zhao, Z. M., Ukidve, A., Gao, Y. S., Kim, J. & Mitragotri, S. Erythrocyte leveraged chemotherapy (ELeCt): nanoparticle assembly on erythrocyte surface to combat lung metastasis. Sci. Adv. 5, eaax9250 (2019).","journal-title":"Sci. Adv."},{"key":"59840_CR75","doi-asserted-by":"publisher","first-page":"23714","DOI":"10.1073\/pnas.1906346116","volume":"116","author":"P Zhang","year":"2019","unstructured":"Zhang, P. et al. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proc. Natl Acad. Sci. USA 116, 23714\u201323723 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59840-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T18:01:59Z","timestamp":1747418519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59840-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59840"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59840-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.-J.C. and Z.Z. are inventors on a patent application with aspects related to this work (titled \u201cAntigen capturing nanoparticle engineered dendritic cells for in situ cancer immunization\u201d, US Provisional Application no. 63\/682,533) filed by the University of Illinois Chicago. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4578"}}